Holy Stone Healthcare (4194) Stock Overview

Holy Stone Healthcare Co., Ltd. engages in the development of therapeutics in Taiwan. It offers RenehaVis, a product designed to relive pain and stiffness of the knee joint; SportVis, a treatment to relive the pain and optimize the recovery of tendon and ligament injuries; TRUD, a treatment that allows mucosal tissue to heal naturally and reduces the symptoms of ulcerative colitis; and GAF, a treatment for anal mucosal lesions. The company is also developing IBD98-M, which is in Phase IIa clinical trials for the treatment of inflammatory bowel diseases; and CA102N to treat colorectal cancer. In addition, it develops ND108E for the treatment of alzheimer's disease; and CA102L, a novel and small molecule conjugated therapeutic agent to treat lymphoma and multiple myeloma. The company was founded in 2001 and is headquartered in Taipei, Taiwan. Holy Stone Healthcare Co., Ltd. is a subsidiary of Holy Stone Enterprise Co.,Ltd.